Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Failure to ensure that everyone has access to prevention options to protect oneself from HIV acquisition, has resulted in at ...

Given recent approvals and a promising pipeline, new biomedical HIV prevention tools for women have the potential to ...

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...

Imagine a world where an HIV prevention method lasts for six months, offering protection without the daily hassle of taking a ...

Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024 ... including by ensuring that nations where trials are conducted are also making the products ...

The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...